

TECHNE CORP /MN/
Form 10-Q
May 12, 2014
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-Q

x **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2014, or

.. **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission file number 0-17272

TECHNE CORPORATION

(Exact name of registrant as specified in its charter)

Minnesota
(State or other jurisdiction of
incorporation or organization)

41-1427402
(I.R.S. Employer
Identification No.)

614 McKinley Place N.E.

Minneapolis, MN
(Address of principal executive offices)

55413
(Zip Code)

(612) 379-8854

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2). Yes No

At May 6, 2014, 36,995,015 shares of the Company's Common Stock (par value \$0.01) were outstanding.

Table of Contents**TABLE OF CONTENTS**

| | Page |
|--|------|
| <u>PART I. FINANCIAL INFORMATION</u> | |
| Item 1. <u>Financial Statements (Unaudited)</u> | |
| <u>Condensed Consolidated Statements of Earnings and Comprehensive Income for the Quarters and Nine Months Ended March 31, 2014 and 2013</u> | 1 |
| <u>Condensed Consolidated Balance Sheets as of March 31, 2014 and June 30, 2013</u> | 2 |
| <u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2014 and 2013</u> | 3 |
| <u>Notes to Condensed Consolidated Financial Statements</u> | 4 |
| Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 8 |
| Item 3. <u>Quantitative and Qualitative Disclosures about Market Risk</u> | 15 |
| Item 4. <u>Controls and Procedures</u> | 16 |
| <u>PART II: OTHER INFORMATION</u> | |
| Item 1. <u>Legal Proceedings</u> | 17 |
| Item 1A. <u>Risk Factors</u> | 17 |
| Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 18 |
| Item 3. <u>Defaults Upon Senior Securities</u> | 18 |
| Item 4. <u>Mine Safety Disclosures</u> | 18 |
| Item 5. <u>Other Information</u> | 18 |
| Item 6. <u>Exhibits</u> | 18 |
| <u>SIGNATURES</u> | 19 |

Table of Contents**PART I. FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS****AND COMPREHENSIVE INCOME***TECHNE Corporation and Subsidiaries**(in thousands, except per share data)**(unaudited)*

| | <i>Quarter Ended</i> | | <i>Nine Months Ended</i> | |
|--|----------------------|-------------|--------------------------|-------------|
| | <i>March 31,</i> | | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |
| Net sales | \$ 95,555 | \$ 80,992 | \$ 265,240 | \$ 231,100 |
| Cost of sales | 27,444 | 19,845 | 77,422 | 59,107 |
| Gross margin | 68,111 | 61,147 | 187,818 | 171,993 |
| Operating expenses: | | | | |
| Selling, general and administrative | 14,666 | 9,982 | 43,613 | 31,266 |
| Research and development | 7,676 | 7,219 | 23,301 | 22,074 |
| Total operating expenses | 22,342 | 17,201 | 66,914 | 53,340 |
| Operating income | 45,769 | 43,946 | 120,904 | 118,653 |
| Other income (expense): | | | | |
| Interest income | 529 | 638 | 1,641 | 1,976 |
| Other non-operating expense, net | (229) | (118) | (604) | (731) |
| Total other income (expense) | 300 | 520 | 1,037 | 1,245 |
| Earnings before income taxes | 46,069 | 44,466 | 121,941 | 119,898 |
| Income taxes | 14,428 | 11,348 | 37,817 | 35,748 |
| Net earnings | 31,641 | 33,118 | 84,124 | 84,150 |
| Other comprehensive income (loss): | | | | |
| Foreign currency translation adjustments | 733 | (9,264) | 11,979 | (4,232) |
| Unrealized gains (losses) on available-for-sale investments, net of tax of \$42, \$6,610, (\$16,887) and (\$2,659), respectively | 5,311 | 11,851 | (30,441) | (4,706) |

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| | | | | |
|---|-----------|-----------|-----------|-----------|
| Other comprehensive income (loss) | 6,044 | 2,587 | (18,462) | (8,938) |
| Comprehensive income | \$ 37,685 | \$ 35,705 | \$ 65,662 | \$ 75,212 |
| Earnings per share: | | | | |
| Basic | \$ 0.86 | \$ 0.90 | \$ 2.28 | \$ 2.28 |
| Diluted | \$ 0.85 | \$ 0.90 | \$ 2.27 | \$ 2.28 |
| Cash dividends per common share: | \$ 0.31 | \$ 0.30 | \$ 0.91 | \$ 0.88 |
| Weighted average common shares outstanding: | | | | |
| Basic | 36,911 | 36,842 | 36,878 | 36,835 |
| Diluted | 37,053 | 36,908 | 36,995 | 36,901 |

See Notes to Condensed Consolidated Financial Statements.

Table of Contents**CONDENSED CONSOLIDATED BALANCE SHEETS***TECHNE Corporation and Subsidiaries**(in thousands, except share and per share data)*

| | <i>March 31,</i> <i>2014</i> <i>(unaudited)</i> | <i>June 30,</i> <i>2013</i> |
|---|---|--------------------------------|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 123,603 | \$ 163,786 |
| Short-term available-for-sale investments | 96,528 | 169,151 |
| Trade accounts receivable, less allowance for doubtful accounts of \$488 and \$428, respectively | 48,501 | 38,183 |
| Other receivables | 1,957 | 1,992 |
| Deferred income taxes | 8,509 | 0 |
| Inventories | 38,386 | 34,877 |
| Prepaid expenses | 2,047 | 1,527 |
| Total current assets | 319,531 | 409,516 |
| Available-for-sale investments | 151,357 | 132,376 |
| Property and equipment, net | 116,649 | 108,756 |
| Goodwill | 144,654 | 84,336 |
| Intangible assets, net | 96,110 | 40,552 |
| Other assets | 2,265 | 2,562 |
| | \$ 830,566 | \$ 778,098 |
| LIABILITIES AND SHAREHOLDERS EQUITY | | |
| Current liabilities: | | |
| Trade accounts payable | \$ 8,418 | \$ 6,236 |
| Salaries, wages and related accruals | 6,462 | 4,025 |
| Accrued expenses | 3,806 | 9,603 |
| Income taxes payable | 5,678 | 2,276 |
| Deferred income taxes | 0 | 9,944 |
| Total current liabilities | 24,364 | 32,084 |
| Deferred income taxes | 29,161 | 8,473 |
| Shareholders' equity: | | |
| Common stock, par value \$.01 per share; authorized 100,000,000; issued and outstanding 36,925,781 and 36,834,678, respectively | 369 | 368 |
| Additional paid-in capital | 142,658 | 134,895 |
| Retained earnings | 637,923 | 587,725 |

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| | | |
|--|------------|------------|
| Accumulated other comprehensive income | (3,909) | 14,553 |
| Total shareholders' equity | 777,041 | 737,541 |
| | \$ 830,566 | \$ 778,098 |

See Notes to Condensed Consolidated Financial Statements.

Table of Contents**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS***TECHNE Corporation and Subsidiaries**(in thousands)**(unaudited)*

| | <i>Nine Months Ended</i> | |
|---|--------------------------|-------------|
| | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> |
| CASH FLOWS FROM OPERATING ACTIVITIES: | | |
| Net earnings | \$ 84,124 | \$ 84,150 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | | |
| Depreciation and amortization | 13,864 | 9,279 |
| Costs recognized on sale of acquired inventory | 4,312 | 3,496 |
| Deferred income taxes | (4,098) | (2,054) |
| Stock-based compensation expense | 2,635 | 1,374 |
| Other | 424 | 382 |
| Change in operating assets and operating liabilities, net of acquisition: | | |
| Trade accounts and other receivables | (6,862) | (2,319) |
| Inventories | (704) | (2,032) |
| Prepaid expenses | (38) | (240) |
| Trade accounts payable and accrued expenses | 575 | (215) |
| Salaries, wages and related accruals | 1,463 | 636 |
| Income taxes payable | 3,146 | 1,118 |
| Net cash provided by operating activities | 98,841 | 93,575 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | |
| Acquisitions, net of cash acquired | (103,149) | 0 |
| Purchase of available-for-sale investments | (89,283) | (89,099) |
| Proceeds from sales of available-for-sale investments | 43,375 | 26,367 |
| Proceeds from maturities of available-for-sale investments | 46,754 | 53,987 |
| Additions to property and equipment | (11,719) | (17,108) |
| Distributions from unconsolidated entities | 85 | 0 |
| Increase in other long-term assets | (60) | (592) |
| Net cash used in investing activities | (113,997) | (26,445) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | | |
| Cash dividends | (33,925) | (32,413) |
| Proceeds from stock option exercises | 5,128 | 824 |
| Excess tax benefit from stock option exercises | 0 | 69 |
| Purchase of common stock for stock bonus plans | 0 | (573) |

| | | |
|--|------------|------------|
| Net cash used in financing activities | (28,797) | (32,093) |
| Effect of exchange rate changes on cash and cash equivalents | 3,770 | (999) |
| Net increase in cash and cash equivalents | (40,183) | 34,038 |
| Cash and cash equivalents at beginning of period | 163,786 | 116,675 |
| Cash and cash equivalents at end of period | \$ 123,603 | \$ 150,713 |

See Notes to Condensed Consolidated Financial Statements.

Table of Contents

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

TECHNE Corporation and Subsidiaries

(unaudited)

A. Basis of Presentation:

The interim unaudited condensed consolidated financial statements of Techne Corporation and Subsidiaries (the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying interim unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature.

A summary of significant accounting policies followed by the Company is detailed in the Company's Annual Report on Form 10-K for fiscal 2013. The Company follows these policies in preparation of the interim unaudited condensed consolidated financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim unaudited condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2013, included in the Company's Annual Report on Form 10-K for fiscal 2013.

B. Acquisition

On July 22, 2013, the Company acquired for cash all of the outstanding shares of Bionostics Holdings, Ltd. (Bionostics) and its U.S. operating subsidiary, Bionostics, Inc. Bionostics is a global leader in the development, manufacture and distribution of control solutions that verify the proper operation of *in-vitro* diagnostic devices primarily utilized in point of care blood glucose and blood gas testing. Bionostics is included in the Company's Clinical Controls segment.

In connection with the Bionostics acquisition, the Company recorded \$14.4 million of developed technology intangible assets that have an estimated useful life of 9 years, \$2.7 million of trade name intangible assets that have an estimated useful life of 5 years, \$2.4 million related to non-compete agreements that have an estimated useful life of 3 years, and \$41.0 million related to customer relationships that have an estimated useful life of 14 years. Intangible asset amortization from this acquisition is not deductible for income tax purposes.

Goodwill recorded as a result of the Bionostics acquisition represents the strategic benefits of growing the Company's product portfolio and the expected revenue growth from increased market penetration from future products and customers. Goodwill from this acquisition is not deductible for income tax purposes.

Transaction costs of \$0.5 million and \$0.6 million were included in the Company's selling, general and administrative costs during the quarters ended September 30, 2013 and June 30, 2013, respectively.

The aggregate purchase price of the acquisition was allocated to the assets acquired and liabilities assumed based on their preliminarily estimated fair values at the date of acquisition. The preliminary estimate of the excess of purchase price over the fair value of net tangible assets acquired was allocated to identifiable intangible assets and goodwill. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as a result of

the Bionostics acquisition (in thousands):

4

Table of Contents

| | |
|-------------------------------------|----------------|
| Current assets | \$ 9,605 |
| Intangible Assets | 60,500 |
| Goodwill | 56,349 |
| Equipment | 2,180 |
| Total assets acquired | 128,634 |
| Liabilities | 3,007 |
| Deferred income taxes | 22,478 |
| Net assets acquired | \$ 103,149 |
| Cash paid, net of cash acquired | \$ 103,149 |

Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of acquisition based on management's assessment. The purchase price allocated to developed technology, trade names, non-compete agreements and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, the non-compete agreement and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The deferred income tax liability represents the estimated future impact of adjustments for the cost to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are not deductible for income tax purposes.

The Company's condensed consolidated financial statements for the quarter and nine months ended March 31, 2014, include Bionostics net sales of \$9.3 million and \$23.5 million, respectively, and net income of \$0.7 million and \$1.0 million, respectively. Included in Bionostics results for the quarter and nine months ended March 31, 2014 were amortization of intangibles of \$1.5 million and \$4.0 million, respectively, and costs recognized on the sales of acquired inventory of \$0.3 million and \$1.4 million, respectively.

C. Available-For-Sale Investments:

The Company's available-for-sale securities are carried at fair value using Level 1 and Level 2 inputs. The fair value of the Company's available-for-sale investments at March 31, 2014 and June 30, 2013 were \$248 million and \$302 million, respectively. The amortized cost basis of the Company's available-for-sale investments at March 31, 2014 and June 30, 2013 were \$235 million and \$241 million, respectively.

Included in the Company's available-for-sale securities is an investment in the common stock and warrants of ChemoCentryx, Inc. (CCXI). The fair value of the Company's investment was \$42.1 million and \$89.6 million at March 31, 2014 and June 30, 2013, respectively. The cost basis of the Company's investment in CCXI was \$29.5 million at both March 31, 2014 and June 30, 2013.

D. Inventories:

Inventories consist of (in thousands):

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| | <i>March 31,</i> <i>2014</i> | <i>June 30,</i> <i>2013</i> |
|----------------|---------------------------------|--------------------------------|
| Raw materials | \$ 9,081 | \$ 5,885 |
| Finished goods | 29,305 | 28,992 |
| | \$ 38,386 | \$ 34,877 |

Table of Contents***E. Property and Equipment:***

Property and equipment consist of (in thousands):

| | <i>March 31,</i> <i>2014</i> | <i>June 30,</i> <i>2013</i> |
|---|---------------------------------|--------------------------------|
| Cost: | | |
| Land | \$ 7,437 | \$ 7,438 |
| Buildings and improvements | 149,739 | 142,656 |
| Machinery and equipment | 51,743 | 39,706 |
| | 208,919 | 189,800 |
| Accumulated depreciation and amortization | (92,270) | (81,044) |
| | \$ 116,649 | \$ 108,756 |

F. Intangible Assets and Goodwill:

Intangible assets and goodwill consist of (in thousands):

| | <i>March 31,</i> <i>2014</i> | <i>June 30,</i> <i>2013</i> |
|--------------------------|---------------------------------|--------------------------------|
| Developed technology | \$ 45,279 | \$ 28,656 |
| Trade names | 20,985 | 17,659 |
| Customer relationships | 49,904 | 8,613 |
| Non-compete agreement | 2,800 | 400 |
| | 118,968 | 55,328 |
| Accumulated amortization | (22,858) | (14,776) |
| | \$ 96,110 | \$ 40,552 |
| Goodwill | \$ 144,654 | \$ 84,336 |

Changes to the carrying amount of net intangible assets for the nine months ended March 31, 2014 consists of (in thousands):

| | |
|----------------------|-----------|
| Beginning balance | \$ 40,552 |
| Acquisition | 60,500 |
| Amortization expense | (7,380) |
| Currency translation | 2,438 |

| | |
|----------------|-----------|
| Ending balance | \$ 96,110 |
|----------------|-----------|

The estimated future amortization expense for intangible assets as of March 31, 2014 is as follows (in thousands):

| | |
|-------------------------------|-----------|
| <i>Period Ending June 30:</i> | |
| 2014 | \$ 2,611 |
| 2015 | 10,442 |
| 2016 | 10,422 |
| 2017 | 9,612 |
| 2018 | 9,562 |
| Thereafter | 53,461 |
| | \$ 96,110 |

The change in the carrying amount of goodwill for the nine months ended March 31, 2014 resulted from the Bionostics acquisition and currency translation.

Table of Contents**G. Earnings Per Share:**

Shares used in the earnings per share computations are as follows (in thousands):

| | <i>Quarter Ended</i> | | <i>Nine Months Ended</i> | |
|---|----------------------|---------------|--------------------------|---------------|
| | <i>March 31,</i> | | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |
| Weighted average common shares outstanding-basic | 36,911 | 36,842 | 36,878 | 36,835 |
| Dilutive effect of stock options | 142 | 66 | 117 | 66 |
| Weighted average common shares outstanding-diluted | 37,053 | 36,908 | 36,995 | 36,901 |

The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 55,000 and 115,000 for the quarter and nine months ended March 31, 2014, respectively. The number of potentially dilutive option shares excluded from the calculation was 222,000 for both the quarter and nine months ended March 31, 2013.

H. Segment Information:

The Company has two reportable segments based on the nature of products (biotechnology and clinical controls). Following is financial information relating to the Company's reportable segments (in thousands):

| | <i>Quarter Ended</i> | | <i>Nine Months Ended</i> | |
|--|----------------------|-------------|--------------------------|-------------|
| | <i>March 31,</i> | | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |
| External sales | | | | |
| Biotechnology | \$ 80,134 | \$ 75,285 | \$ 223,881 | \$ 214,416 |
| Clinical Controls | 15,421 | 5,707 | 41,359 | 16,684 |
| Consolidated net sales | \$ 95,555 | \$ 80,992 | \$ 265,240 | \$ 231,100 |
| Earnings before income taxes | | | | |
| Biotechnology | \$ 44,593 | \$ 43,246 | \$ 120,589 | \$ 117,123 |
| Clinical Controls | 3,157 | 2,247 | 7,225 | 6,498 |
| Segment earnings before income taxes | 47,750 | 45,493 | 127,814 | 123,621 |
| Unallocated corporate expenses and equity method investee losses | (1,681) | (1,027) | (5,873) | (3,723) |
| Consolidated earnings before income taxes | \$ 46,069 | \$ 44,466 | \$ 121,941 | \$ 119,898 |

I. Accumulated Other Comprehensive Income:

Accumulated other comprehensive income (loss) consists of (in thousands):

| | <i>March 31,</i> <i>2014</i> | <i>June 30,</i> <i>2013</i> |
|---|---------------------------------|--------------------------------|
| Foreign currency translation adjustments | \$ (12,302) | \$ (24,281) |
| Net unrealized gain on available-for-sale investments, net of tax | 8,393 | 38,834 |
| | \$ (3,909) | \$ 14,553 |

Table of Contents

J. Subsequent Event:

On April 1, 2014, the Company entered into an Agreement of Investment and Merger (the Agreement) with CyVek, Inc. (CyVek). Pursuant to the terms of the Agreement, the Company invested \$10.0 million in CyVek and received shares of Common Stock representing approximately 20% of the outstanding voting stock of CyVek.

If, within twelve months of the date of the Agreement, CyVek meets commercial milestones related to the sale of its products, the Company will acquire CyVek through a merger, with CyVek surviving as a wholly-owned subsidiary of the Company. If the Merger is consummated, the Company will make an initial payment of \$60.0 million to the other stockholders of CyVek. The purchase price payable at the closing of the Merger may be adjusted based on the final levels of cash, indebtedness and transaction expenses of CyVek as of the closing. The Company will also pay CyVek's other stockholders up to \$35.0 million based on the revenue generated by CyVek's products and related products before the date that is 30 months from the closing of the Merger. The Company will also pay CyVek's other stockholders 50% of the amount, if any, by which the revenue from CyVek's products and related products exceeds \$100 million in calendar year 2020.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS**

OVERVIEW

Techne Corporation and Subsidiaries (the Company), d/b/a Bio-Techne, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

The Company has two reportable segments based on the nature of its products (biotechnology and clinical controls). R&D Systems, Inc.'s Biotechnology Division, R&D Systems Europe Ltd., Tocris Holdings Limited, R&D Systems China Co., Ltd., BiosPacific, Inc. and Boston Biochem, Inc. operating segments are included in the biotechnology reporting segment. The Company's biotechnology reporting segment develops, manufactures and sells biotechnology research and diagnostic products world-wide. The Company's clinical controls reporting segment, which consists of R&D Systems, Inc.'s Clinical Controls Division and Bionostics, Inc., develop and manufacture controls and calibrators for sale world-wide.

RESULTS OF OPERATIONS

Consolidated net sales increased 18.0% and 14.8% for the quarter and nine months ended March 31, 2014, respectively, compared to the quarter and nine months ended March 31, 2013. Consolidated net earnings decreased 4.5% and were unchanged for the quarter and nine months ended March 31, 2014, respectively, compared to the same prior-year periods. Consolidated net sales for the quarter and nine months ended March 31, 2014 were affected by the Bionostics acquisition, which closed in July 2013, and changes in foreign currency exchange rates from the same prior-year periods. Included in consolidated net sales for the quarter and nine months ended March 31, 2014 were \$9.3 million and \$23.5 million of acquisition-related net sales. A weaker U.S. dollar as compared to foreign currencies increased sales by \$1.0 million and \$2.2 million in the quarter and nine months ended March 31, 2014, respectively, from the comparable prior-year periods.

Table of Contents**Net Sales**

Consolidated organic net sales, excluding the impact of the acquisition and the effect of the change from the prior year in exchange rates used to convert sales in foreign currencies (primarily British pound sterling, euros and Chinese yuan) into U.S. dollars, were as follows (in thousands):

| | <i>Quarter Ended</i> | | <i>Nine Months Ended</i> | |
|---|----------------------|-------------|--------------------------|-------------|
| | <i>March 31,</i> | | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |
| Consolidated net sales | \$ 95,555 | \$ 80,992 | \$ 265,240 | \$ 231,100 |
| Organic sales adjustments: | | | | |
| Acquisition | (9,311) | 0 | (23,507) | 0 |
| Impact of foreign currency fluctuations | (977) | 0 | (2,230) | 0 |
| Consolidated organic net sales | \$ 85,267 | \$ 80,992 | \$ 239,503 | \$ 231,100 |
| Organic sales growth (decline) | 5.3% | (3.0%) | 3.6% | (0.9%) |

Net sales by reportable segment were as follows (in thousands):

| | <i>Quarter Ended</i> | | <i>Nine Months Ended</i> | |
|------------------------|----------------------|-------------|--------------------------|-------------|
| | <i>March 31,</i> | | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |
| Biotechnology | \$ 80,134 | \$ 75,285 | \$ 223,881 | \$ 214,416 |
| Clinical Controls | 15,421 | 5,707 | 41,359 | 16,684 |
| Consolidated net sales | \$ 95,555 | \$ 80,992 | \$ 265,240 | \$ 231,100 |

Biotechnology segment net sales increased \$4.8 million (6.4%) and \$9.5 million (4.4%) for the quarter and nine months ended March 31, 2014 compared to the same prior-year periods. The increase in net sales for the quarter and nine months ended March 31, 2014 was affected by changes in exchange rates from the comparable prior-year periods, which increased sales by \$1.0 million and \$2.2 million for the quarter and nine months ended March 31, 2014, as noted above. Included in consolidated net sales for the quarter and nine months ended March 31, 2014 were \$0.9 million and \$1.8 million, respectively, of sales of new biotechnology products that had their first sale in fiscal 2014.

Biotechnology segment sales growth (decline) from the same prior-year periods were as follows:

| | <i>Reported</i> | | <i>Excluding Currency Impact</i> | |
|---|----------------------|-------------|----------------------------------|-------------|
| | <i>Quarter Ended</i> | | <i>Quarter Ended</i> | |
| | <i>March 31,</i> | | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |
| U.S. industrial, pharmaceutical and biotechnology | 4.2% | (2.5%) | 4.2% | (2.5%) |

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| | | | | |
|---|---------|---------|---------|---------|
| U.S. academic | (11.7%) | (8.5%) | (11.7%) | (8.5%) |
| Europe | 12.9% | (10.8%) | 7.7% | (10.3%) |
| China | 4.8% | 25.3% | 2.0% | 24.9% |
| Pacific rim distributors, excluding China | 12.0% | 9.6% | 12.0% | 9.6% |

Table of Contents

| | <i>Reported</i> | | <i>Excluding Currency Impact</i> | |
|---|--------------------------|-------------|----------------------------------|-------------|
| | <i>Nine Months Ended</i> | | <i>Nine Months Ended</i> | |
| | <i>March 31,</i> | | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |
| U.S. industrial, pharmaceutical and biotechnology | 4.4% | (4.2%) | 4.4% | (4.2%) |
| U.S. academic | (9.6%) | (5.5%) | (9.6%) | (5.5%) |
| Europe | 6.7% | (6.1%) | 2.4% | (2.0%) |
| China | 26.6% | 20.2% | 23.3% | 19.4% |
| Pacific rim distributors, excluding China | 11.1% | 4.7% | 11.1% | 4.7% |

Biotechnology segment net sales consisted of the following:

| | <i>Nine Months</i> |
|--|--------------------|
| | <i>Ended</i> |
| | <i>March 31,</i> |
| | <i>2014</i> |
| United States: | |
| Industrial, pharmaceutical and biotechnology | 29% |
| Academic | 12% |
| Other | 12% |
| | 53% |
| Europe | 29% |
| China | 6% |
| Pacific rim distributors, excluding China | 10% |
| Rest of world | 2% |
| | 100% |

Clinical Controls segment net sales increased \$9.7 million and \$24.7 million for the quarter and nine months ended March 31, 2014, respectively, compared to the same prior-year periods. The increase in net sales for the quarter and nine months ended March 31, 2014 was affected by the acquisition of Bionostics in July 2013. Excluding Bionostic sales, Clinical Controls segment sales growth was \$0.4 million (7.1%) and \$1.2 million (7.0%) for the quarter and nine months ended March 31, 2014, respectively. These increases were a result of strong demand for its products and solid execution by the team.

Gross Margins

Fluctuations in gross margins, as a percentage of net sales, are typically the result of changes in foreign currency exchange rates, changes in product mix and seasonality. Such fluctuations are normal and expected to continue in future periods.

Consolidated gross margins for the quarters and nine months ended March 31, 2014 and 2013 were negatively impacted as a result of purchase accounting related to inventory and intangible assets acquired in the current and prior

fiscal years. Under purchase accounting, inventory is valued at fair value less expected selling and marketing costs, resulting in reduced margins in future periods as the inventory is sold.

Table of Contents

A reconciliation of the reported consolidated gross margin percentages, adjusted for acquired inventory sold and intangible amortization included in cost of sales, is as follows:

| | <i>Quarter Ended</i> | | <i>Nine Months Ended</i> | |
|--|----------------------|-------------|--------------------------|-------------|
| | <i>March 31,</i> | | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |
| Consolidated gross margin percentage | 71.3% | 75.5% | 70.8% | 74.4% |
| Identified adjustments | | | | |
| Costs recognized upon sale of acquired inventory | 1.2% | 1.3% | 1.6% | 1.5% |
| Amortization of intangibles | 1.1% | 0.9% | 1.2% | 1.0% |
| Adjusted gross margin percentage | 73.6% | 77.7% | 73.6% | 76.9% |

Segment gross margins, as a percentage of net sales, were as follows:

| | <i>Quarter Ended</i> | | <i>Nine Months Ended</i> | |
|-------------------|----------------------|-------------|--------------------------|-------------|
| | <i>March 31</i> | | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |
| Biotechnology | 77.3% | 77.5% | 76.9% | 76.4% |
| Clinical Controls | 39.8% | 49.0% | 38.1% | 49.0% |
| Consolidated | 71.3% | 75.5% | 70.8% | 74.4% |

Biotechnology segment gross margin percentages for the quarter and nine months ended March 31, 2014 remained stable from the same prior-year periods. Clinical Controls segment gross margin percentages for the quarter and nine months ended March 31, 2014 decreased from the comparable prior-year period mainly as a result of intangible amortization and cost recognized upon the sale of inventory acquired in July 2013, in conjunction with the acquisition of Bionostics.

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased \$4.7 million (46.9%) and \$12.3 million (39.5%) for the quarter and nine months ended March 31, 2014, respectively, from the same prior-year periods. The increase for the quarter and nine months ended March 31, 2014 was mainly a result of the Bionostics acquisition, including \$1.0 million and \$3.1 million, respectively, of selling, general and administrative expense by Bionostics, and \$1.1 million and \$2.9 million of intangible amortization for the quarter and nine months ended March 31, 2014, respectively. Selling, general and administrative expenses included \$0.4 million and \$0.9 million of professional fees related to acquisition activities for the quarter and nine months ended March 31, 2014, respectively. These expenses also included an increase in stock compensation expense of \$0.5 million and \$1.3 million for the quarter and nine months ended March 31, 2014, respectively, as a result of increased options and restricted stock granted in fiscal 2014. The remainder of the increase in selling, general and administrative expense was due primarily to additional investment in commercial resources and administrative infrastructure since the third quarter of fiscal 2013.

Consolidated selling, general and administrative expenses were composed of the following (in thousands):

| | <i>Quarter Ended</i> | | <i>Nine Months Ended</i> | |
|---|----------------------|-------------|--------------------------|-------------|
| | <i>March 31,</i> | | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |
| Biotechnology | \$ 10,655 | \$ 8,941 | \$ 31,011 | \$ 27,304 |
| Clinical Controls | 2,533 | 375 | 7,316 | 1,173 |
| Unallocated corporate expenses | 1,478 | 666 | 5,286 | 2,789 |
| Consolidated selling, general and administrative expenses | \$ 14,666 | \$ 9,982 | \$ 43,613 | \$ 31,266 |

Table of Contents***Research and Development Expenses***

Research and development expenses for the quarter and nine months ended March 31, 2014 increased \$0.5 million (6.3%) and \$1.2 million (5.6%), respectively, from the same prior-year periods. Included in research and development expenses for the quarter and nine months ended March 31, 2014 were \$0.2 million and \$0.6 million, respectively, of expenses by Bionostics. The remainder of the increase in research and development expense for the quarter and nine months was due to personnel and supply costs associated with the continuous development and release of new high-quality biotechnology products. The Company expects research and development expenses to continue to increase in future periods as a result of its ongoing product development program.

Research and development expenses were composed of the following (in thousands):

| | <i>Quarter Ended</i> | | <i>Nine Months Ended</i> | |
|--|----------------------|-------------|--------------------------|-------------|
| | <i>March 31,</i> | | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |
| Biotechnology | \$ 7,212 | \$ 7,015 | \$ 22,011 | \$ 21,470 |
| Clinical Controls | 464 | 204 | 1,290 | 604 |
| Consolidated research and development expenses | \$ 7,676 | \$ 7,219 | \$ 23,301 | \$ 22,074 |

Interest Income

Interest income for the quarter and nine months ended March 31, 2014 was \$0.5 million and \$1.6 million, respectively, compared to \$0.6 million and \$2.0 million, respectively, for the quarter and nine months ended March 31, 2013. The decrease was primarily due to lower cash balances as a result of the Bionostics acquisition in July 2013.

Other Non-operating Expense, Net

Other non-operating expense, net, consists mainly of foreign currency transaction gains and losses, rental income, building expenses related to rental property, and the Company's share of losses by equity method investees. Amounts were as follows (in thousands):

| | <i>Quarter Ended</i> | | <i>Nine Months Ended</i> | |
|--|----------------------|-------------|--------------------------|-------------|
| | <i>March 31,</i> | | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |
| Foreign currency gains | \$ 8 | \$ 289 | \$ 93 | \$ 360 |
| Rental income | 248 | 196 | 737 | 581 |
| Building expenses related to rental property | (485) | (572) | (1,434) | (1,558) |
| Losses by equity method investees | 0 | (31) | 0 | (114) |
| Other non-operating expense, net | \$ (229) | \$ (118) | \$ (604) | \$ (731) |

Income Taxes

Income taxes for the quarter and nine months ended March 31, 2014 were provided at rates of 31.3% and 31.0%, respectively, of consolidated earnings before income taxes compared to 25.5% and 29.8%, respectively for the quarter and nine months ended March 31, 2013. Included in income tax expense for the quarter and nine months ended March 31, 2013 was a \$1.2 million credit for research and development expenses for the period of January 2012 through March 2013. Also included in income tax expense for the quarter and nine months ended March 31, 2013 were credits to U.S. income taxes of \$1.1 million and \$0.5 million, respectively, related to changes in estimates of foreign source income.

The Company expects the income tax rate for the remainder of fiscal 2014 to range from 30% to 32%.

Table of Contents**Net Earnings**

Adjusted consolidated net earnings are as follows:

| | <i>Quarter Ended</i> | | <i>Nine Months Ended</i> | |
|--|----------------------|-------------|--------------------------|-------------|
| | <i>March 31,</i> | | <i>March 31,</i> | |
| | <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |
| Net earnings | \$ 31,641 | \$ 33,118 | \$ 84,124 | \$ 84,150 |
| Identified adjustments: | | | | |
| Costs recognized upon sale of acquired inventory | 1,177 | 1,032 | 4,312 | 3,496 |
| Amortization of intangibles | 2,605 | 1,252 | 7,380 | 3,806 |
| Acquisition related professional fees | 395 | 0 | 927 | 0 |
| Tax impact of above adjustments | (1,169) | (619) | (3,552) | (1,965) |
| Tax impact of research and development credit | 0 | (1,186) | (476) | (1,186) |
| Tax impact of foreign source income | 36 | (1,138) | 136 | (500) |
| Net earnings adjusted | \$ 34,685 | \$ 32,459 | \$ 92,851 | \$ 87,801 |
| Adjusted net earnings growth | | 6.9% | | 5.8% |

LIQUIDITY AND CAPITAL RESOURCES

At March 31, 2014, cash and cash equivalents and available-for-sale investments were \$371 million compared to \$465 million at June 30, 2013. Included in available-for-sale-investments at March 31, 2014 was the fair value of the Company's investment in ChemoCentryx, Inc. (CCXI) of \$42.1 million. The fair value of the Company's CCXI investment at June 30, 2013 was \$89.6 million.

At March 31, 2014, approximately 47%, 47%, and 6% of the Company's cash and cash equivalents of \$124 million are located in the U.S., United Kingdom and China, respectively. At March 31, 2014, approximately 95% of the Company's available-for-sale investment accounts are located in the U.S., with the remaining 5% in China. The Company has either paid U.S. income taxes on its undistributed foreign earnings or intends to indefinitely reinvest the undistributed earnings in the foreign operations.

The Company believes it can meet its cash and working capital requirements, capital addition, share repurchase, cash dividend and investment strategy needs for at least the next twelve months through currently available funds, cash generated from operations and maturities or sales of available-for-sale investments. Future acquisition strategies may, or may not, require outside sources of funding.

Cash Flows From Operating Activities

The Company generated cash of \$98.8 million from operating activities in the first nine months of fiscal 2014 compared to \$93.6 million in the first nine months of fiscal 2013. The increase from the prior year was primarily due to increased net earnings after adjustment for non-cash expenses related to depreciation, amortization and cost recognized on sale of acquired inventory.

Cash Flows From Investing Activities

On July 22, 2013, the Company acquired, for a net purchase price of \$103 million cash, all of the outstanding shares of Bionostics Holdings, Ltd. (Bionostics) and its U.S. operating subsidiary, Bionostics, Inc. Bionostics is a global leader in the development, manufacture and distribution of control solutions that verify the proper operation of *in-vitro* diagnostic devices primarily utilized in point of care blood glucose and blood gas testing. The acquisition was financed through cash and cash equivalents on hand.

Table of Contents

During the nine months ended March 31, 2014, the Company purchased \$89.3 million and had sales or maturities of \$90.1 million of available-for-sale investments. During the nine months ended March 31, 2013, the Company purchased \$89.1 million and had sales or maturities of \$80.4 million of available-for-sale investments. The Company's investment policy is to place excess cash in municipal and corporate bonds and other investments with maturities of less than three years. The objective of this policy is to obtain the highest possible return while minimizing risk and keeping the funds accessible.

Capital expenditures for fixed assets for the first nine months of fiscal 2014 and 2013 were \$11.7 million and \$17.1 million, respectively. Included in capital expenditures for the first nine months of fiscal 2014 and 2013 was \$5.8 million and \$15.1 million, respectively, related to expansion and remodeling of office and laboratory space at the Company's Minneapolis, Minnesota facility. The remaining capital additions were mainly for laboratory and computer equipment. Capital expenditures in the remainder of fiscal 2014 are expected to be approximately \$2.8 million. Capital expenditures are expected to be financed through currently available funds and cash generated from operating activities.

Subsequent to the end of the third quarter of fiscal 2014, the Company invested \$10.0 million in CyVek, Inc. (CyVek) representing approximately 20% of the outstanding voting stock of CyVek.

Cash Flows From Financing Activities

During the first nine months of fiscal 2014 and 2013, the Company paid cash dividends of \$33.9 million and \$32.4 million, respectively, to all common shareholders. On April 28, 2014, the Company announced the payment of a \$0.31 per share cash dividend. The dividend of approximately \$11.5 million will be payable May 23, 2014 to all common shareholders of record on May 9, 2014.

Cash of \$5.1 million and \$0.8 million was received during the first nine months of fiscal 2014 and 2013, respectively, from the exercise of stock options. The Company also recognized excess tax benefits from stock option exercises of \$0.1 million for the nine months ended March 31, 2013.

During the first nine months of fiscal 2013, the Company repurchased 8,324 shares of common stock for its employee stock bonus plans at a cost of \$0.6 million. No contribution to the employee stock bonus plan was made during the first nine months of fiscal 2014.

CONTRACTUAL OBLIGATIONS

There were no material changes outside the ordinary course of business in the Company's contractual obligations during the quarter ended March 31, 2014.

CRITICAL ACCOUNTING POLICIES

The Company's significant accounting policies are discussed in the Company's Annual Report on Form 10-K for fiscal 2013 and are incorporated herein by reference. The application of certain of these policies requires judgments and estimates that can affect the results of operations and financial position of the Company. Judgments and estimates are used for, but not limited to, valuation of available-for-sale investments, inventory valuation and allowances, valuation of intangible assets and goodwill and valuation of investments in unconsolidated entities. There have been no significant changes in estimates in fiscal 2014 that would require disclosure. There have been no changes to the Company's policies in fiscal 2014.

Table of Contents**FORWARD LOOKING INFORMATION AND CAUTIONARY STATEMENTS**

This quarterly report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include those regarding the Company's expectations as to the effect of changes to accounting policies, the amount of capital expenditures for the remainder of the fiscal year, the source of funding for capital expenditure requirements, the sufficiency of currently available funds for meeting the Company's needs, the impact of fluctuations in foreign currency exchange rates, and expectations regarding gross margin fluctuations, increasing research and development expenses, increasing selling, general and administrative expenses and income tax rates. These statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the introduction and acceptance of new products, general national and international economic conditions, increased competition, the reliance on internal manufacturing and related operations, the impact of currency exchange rate fluctuations, economic instability in Eurozone countries, the recruitment and retention of qualified personnel, the impact of governmental regulation, maintenance of intellectual property rights, credit risk and fluctuation in the market value of the Company's investment portfolio, unseen delays and expenses related to facility improvements, and the success of financing efforts by companies in which the Company has invested. For additional information concerning such factors, see the Company's Annual Report on Form 10-K for fiscal 2013 as filed with the Securities and Exchange Commission.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

At March 31, 2014, the Company had a portfolio of fixed income debt securities, excluding those classified as cash and cash equivalents, of \$206 million. These securities, like all fixed income instruments, are subject to interest rate risk and will decline in value if market interest rates increase. As the Company's fixed income securities are classified as available-for-sale, no gains or losses are recognized by the Company in its consolidated statements of earnings due to changes in interest rates unless such securities are sold prior to maturity. The Company generally holds its fixed income securities until maturity and, historically, has not recorded any material gains or losses on any sale prior to maturity.

At March 31, 2014, the Company held an investment in the common stock of CCXI. The investment was included in short-term available-for-sale investments at its fair value of \$42.1 million. At March 31, 2014, the potential loss in fair value due to a 10% decrease in the market value of CCXI was \$4.2 million.

The Company operates internationally, and thus is subject to potentially adverse movements in foreign currency exchange rates. For the nine months ended March 31, 2014, approximately 30% of consolidated net sales were made in foreign currencies, including 15% in euros, 5% in British pound sterling, 4% in Chinese yuan and the remaining 6% in other European currencies. As a result, the Company is exposed to market risk mainly from foreign exchange rate fluctuations of the euro, British pound sterling and the Chinese yuan as compared to the U.S. dollar as the financial position and operating results of the Company's foreign operations are translated into U.S. dollars for consolidation.

Month-end average exchange rates between the British pound sterling, euro and Chinese yuan and the U.S. dollar, which have not been weighted for actual sales volume in the applicable months in the periods, were as follows:

| <i>Quarter Ended</i> | | <i>Nine Months Ended</i> | |
|----------------------|-------------|--------------------------|-------------|
| <i>March 31,</i> | | <i>March 31,</i> | |
| <i>2014</i> | <i>2013</i> | <i>2014</i> | <i>2013</i> |

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| | | | | |
|------------------------|---------|---------|---------|---------|
| Euro | \$ 1.37 | \$ 1.32 | \$ 1.36 | \$ 1.29 |
| British pound sterling | 1.66 | 1.54 | 1.62 | 1.58 |
| Chinese yuan | .163 | .161 | .164 | .160 |

Table of Contents

The Company's exposure to foreign exchange rate fluctuations also arises from trade receivables and intercompany payables denominated in one currency in the financial statements, but receivable or payable in another currency. At March 31, 2014, the Company had the following trade receivable and intercompany payables denominated in one currency but receivable or payable in another currency (in thousands):

| | <i>Denominated Currency</i> | <i>U.S. Dollar Equivalent</i> |
|---------------------------|---------------------------------|-----------------------------------|
| Accounts receivable in: | | |
| Euros | £ 1,403 | \$ 2,338 |
| Other European currencies | £ 1,173 | \$ 1,955 |
| Intercompany payable in: | | |
| Euros | £ 509 | \$ 848 |
| U.S. dollars | £ 5,617 | \$ 9,361 |
| U.S. dollars | yuan 8,273 | \$ 1,344 |

All of the above balances are revolving in nature and are not deemed to be long-term balances. The Company does not enter into foreign exchange forward contracts to reduce its exposure to foreign currency rate changes on forecasted intercompany foreign currency denominated balance sheet positions. Foreign currency transaction gains and losses are included in Other non-operating expense in the Consolidated Statement of Earnings and Comprehensive Income. The effect of translating net assets of foreign subsidiaries into U.S. dollars are recorded on the Consolidated Balance Sheet as part of Accumulated other comprehensive income.

The effects of a hypothetical simultaneous 10% appreciation in the U.S. dollar from March 31, 2014 levels against the euro, British pound sterling and Chinese yuan are as follows (in thousands):

| | |
|---|----------|
| Decrease in translation of 2014 earnings into U.S. dollars (annualized) | \$ 2,585 |
| Decrease in translation of net assets of foreign subsidiaries | 16,967 |
| Additional transaction losses | 1,071 |

ITEM 4. CONTROLS AND PROCEDURES

As of the end of the period covered by this report, the Company's management conducted an evaluation, under the supervision and with the participation of the principal executive officer and principal financial officer, of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 as amended (the Exchange Act)).

Based on this evaluation, the principal executive officer and principal financial officer concluded that the Company's disclosure controls and procedures were not effective as a result of the previously identified material weakness in internal control over financial reporting, the nature of which is summarized below.

Previously Reported Material Weakness in Internal Control Over Financial Reporting

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. The Company has identified a material weakness in the

design, implementation and operating effectiveness of general IT controls (GITCs) intended to ensure that access to financial applications and data was adequately restricted to appropriate personnel, and that program changes to particular financial applications are documented, tested, and moved into the production environment only by individuals separate from the development function. As a result, certain classes of transactions subject to controls that rely upon information generated by the Company's IT systems that are subject to the operation of the GITCs, including the completeness, existence, and accuracy of revenue and accounts receivable, allow for a reasonable possibility that a misstatement is not adequately prevented or detected through the operation of management's system of internal control over financial reporting.

Table of Contents

Remediation Efforts in Fiscal 2014

Promptly following the identification of the material weakness as described above, management, with the oversight of the Audit Committee of the Board of Directors, began taking steps to remediate the material weakness.

During the nine months ended March 31, 2014, the Company enhanced its internal testing approach, including performing additional procedures and expanding the documentation for select controls, to ensure the completeness, existence and accuracy of system generated information used to support the operation of the controls. The Company anticipates that the enhanced testing and documentation, in addition to possible expansion of human resources to improve segregation of duties, will be adequate to remediate the material weakness in future quarters, and that testing to confirm elimination of the material weakness will be complete by the end of the 2014 fiscal year.

In light of the material weakness identified above, the Company performed additional analysis and other post-closing procedures to ensure that the Company's consolidated financial statements were prepared in accordance with generally accepted accounting principles and accurately reflect its financial position and results of operation as of and for the quarter and nine months ended March 31, 2014. As a result, notwithstanding the material weakness as described above, management concluded that the consolidated financial statements included in this Form 10-Q present fairly, in all material respects, the Company's financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America.

Changes in Internal Control over Financial Reporting

There was no change in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the Company's most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting, except for the remediation steps to address the material weakness in internal control over financial reporting described above.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

As of May 12, 2014, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company's business, results of operations, financial condition or cash flows.

ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors previously disclosed in Part I, Item 1A, Risk Factors, of the Company's Annual Report on Form 10-K for the year ended June 30, 2013.

Table of Contents**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

The following table sets forth the repurchases of Company common stock for the quarter ended March 31, 2014:

| Period | Total Number of Shares Purchased | Average Price Paid Per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
|----------------|----------------------------------|------------------------------|--|--|
| 1/1/14-1/31/14 | 0 | \$ 0 | 0 | \$ 125.2 million |
| 2/1/14-2/28/14 | 0 | \$ 0 | 0 | \$ 125.2 million |
| 3/1/14-3/31/14 | 0 | \$ 0 | 0 | \$ 125.2 million |
| Total | 0 | \$ 0 | 0 | \$ 125.2 million |

In April 2009, the Company authorized a plan for the repurchase and retirement of \$60.0 million of its common stock. The plan does not have an expiration date. In October 2012, the Company increased the amount authorized under the plan by \$100 million.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

See exhibit index following the signature page.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TECHNE CORPORATION
(Company)

Date: May 12, 2014

/s/ Charles R. Kummeth
Charles R. Kummeth
Principal Executive Officer

Date: May 12, 2014

/s/ James Hippel
James Hippel
Principal Financial Officer

EXHIBIT INDEX

TO

FORM 10-Q

TECHNE CORPORATION

| Exhibit # | Description |
|-----------|---|
| 31.1 | Section 302 Certification |
| 31.2 | Section 302 Certification |
| 32.1 | Section 906 Certification |
| 32.2 | Section 906 Certification |
| 101 | The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Earnings and Comprehensive Income, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv) Notes to the Condensed Consolidated Financial Statements. |